Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) EBT Margin (2016 - 2025)

Ptc Therapeutics has reported EBT Margin over the past 14 years, most recently at 843.41% for Q4 2025.

  • Quarterly results put EBT Margin at 843.41% for Q4 2025, down 79898.0% from a year ago — trailing twelve months through Dec 2025 was 31.96% (up 2660.0% YoY), and the annual figure for FY2025 was 31.96%, up 1304.0%.
  • EBT Margin for Q4 2025 was 843.41% at Ptc Therapeutics, down from 10.94% in the prior quarter.
  • Over the last five years, EBT Margin for PTCT hit a ceiling of 211.29% in Q4 2021 and a floor of 843.41% in Q4 2025.
  • Median EBT Margin over the past 5 years was 61.25% (2023), compared with a mean of 75.82%.
  • Biggest five-year swings in EBT Margin: soared 31773bps in 2023 and later tumbled -79898bps in 2025.
  • Ptc Therapeutics' EBT Margin stood at 211.29% in 2021, then plummeted by -154bps to 113.31% in 2022, then skyrocketed by 280bps to 204.42% in 2023, then crashed by -122bps to 44.42% in 2024, then plummeted by -1799bps to 843.41% in 2025.
  • The last three reported values for EBT Margin were 843.41% (Q4 2025), 10.94% (Q3 2025), and 39.72% (Q2 2025) per Business Quant data.